Outcomes after coronary angiography in individuals with elevated lipoprotein(a)

Kelvin Supriami1,2, Christian C Faaborg-Andersen2,3, So Mi Jemma Cho2,4,5

  • 1Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, CPZN 3.187, Boston, MA 02114, USA.

Insights

Elevated lipoprotein(a) [Lp(a)] significantly increases coronary artery disease (CAD) risk. Very high Lp(a) levels after invasive coronary angiography are linked to more severe atherosclerosis and higher rates of adverse cardiovascular events and mortality.

Area of Science:

  • Cardiology
  • Genetics
  • Vascular Biology

Background:

  • Elevated lipoprotein(a) [Lp(a)] is a known independent risk factor for coronary artery disease (CAD).
  • Long-term outcome data following invasive coronary angiography (ICA) in patients with elevated Lp(a) are limited.
  • Understanding the impact of Lp(a) on atherosclerosis burden and clinical outcomes post-ICA is crucial for risk stratification.

Purpose of the Study:

  • To investigate the association between Lp(a) levels and clinical outcomes after index ICA.
  • To assess the relationship between Lp(a) levels and atherosclerotic plaque burden.
  • To identify individuals with elevated Lp(a) who may benefit from targeted risk-reduction strategies.

Main Methods:

  • Retrospective analysis of 5118 participants who underwent ICA between 2000 and 2023 with Lp(a) measurements.
  • Categorization of Lp(a) levels into normal, intermediate, high, and very high.
  • Assessment of angiographic characteristics, CAD presentation, and clinical outcomes including acute myocardial infarction, revascularization, in-stent restenosis, and mortality.

Main Results:

  • 19.0% of participants had very high Lp(a).
  • Very high Lp(a) was associated with severe obstructive CAD, left main disease, and higher Gensini scores.
  • Over a median follow-up of 16.87 years, very high Lp(a) correlated with increased risk of acute myocardial infarction, revascularization, in-stent restenosis, and mortality.
  • Among those undergoing bypass surgery, very high Lp(a) was linked to a higher likelihood of subsequent percutaneous coronary intervention.

Conclusions:

  • Elevated Lp(a) is associated with a greater burden of coronary atherosclerosis.
  • Significant residual risk for adverse outcomes persists after ICA in individuals with elevated Lp(a).
  • Targeted risk-reduction strategies are needed for patients with elevated Lp(a).
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
563
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
202
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
213
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
843
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
738